公开(公告)号：US5004802A

公开(公告)日：1991-04-02

申请号：US884418

申请日：1986-07-11

申请人： Cornelis Kluft

发明人： Cornelis Kluft

IPC分类号： A61K35/14 ,  A61K35/16 ,  A61K38/00 ,  A61K38/16 ,  A61K38/55 ,  C07K14/745 ,  C07K14/81

CPC分类号： C07K14/8132 ,  A61K38/00 ,  Y10S530/829

摘要： A protein called PA binding protein has been isolated which binds specifically and reversibly to tissue plasminogen activator. The protein is characterized by a molecular mass of about 100,000 daltons, and electrophoretic mobility in agarose at pH 8.6 equal to that of plasma .beta.-globulins and an isoelectric point of 6.5 to 7.0. The protein is thermostable up to at least 56.degree. C. and is cleared from the circulation with a half life on the order of days.

摘要翻译： 已经分离出称为PA结合蛋白的蛋白质，其特异性和可逆地结合于组织纤溶酶原激活物。 该蛋白质的特征在于约100,000道尔顿的分子量，并且在pH 8.6的琼脂糖中的电泳迁移率等于血浆β-球蛋白的电泳迁移率，等电点为6.5至7.0。 该蛋白质耐热至多达56℃，并从循环中清除半衰期约为几天。

公开(公告)号：US20160318990A1

公开(公告)日：2016-11-03

申请号：US15108194

申请日：2014-12-26

申请人： JAPAN BLOOD PRODUCTS ORGANIZATION

发明人： Shusei UNO ,  Momoko OTAKI ,  Kouji MURAKAMI ,  Shoji IDENO

IPC分类号： C07K14/75

CPC分类号： C07K14/75 ,  C07K14/8121 ,  C07K14/8132 ,  C12N2510/02 ,  C12N2511/00

摘要： The present invention provides a recombinant strain highly producing fibrinogen which is an animal cell strain coexpressing a fibrinogen and an α2PI and/or PAI-2, genes encoding Aα chain, Bβ chain and γ chain of fibrinogen, a production method of a recombinant strain highly producing fibrinogen, including introducing gene(s) encoding α2PI and/or PAI-2 into an animal cell, and coexpressing fibrinogen and α2PI and/or PAI-2 in the animal cell, and a production method of a recombinant fibrinogen including culturing a recombinant strain highly producing fibrinogen in a medium, and recovering fibrinogen from the obtained culture.

摘要翻译： 本发明提供了一种高产纤维蛋白原的重组菌株，其是共表达纤维蛋白原的动物细胞株和α2PI和/或PAI-2，编码纤维蛋白原的Aα链，Bβ链和γ链的基因，重组菌株的制备方法高度 产生纤维蛋白原，包括将编码α2PI和/或PAI-2的基因导入动物细胞，以及共表达动物细胞中的纤维蛋白原和α2PI和/或PAI-2，以及重组纤维蛋白原的制备方法，包括培养重组 在培养基中高度产生纤维蛋白原，并从所得培养物中回收纤维蛋白原。

公开(公告)号：US20140315227A1

公开(公告)日：2014-10-23

申请号：US14358116

申请日：2012-11-15

申请人： National University Corporation Hamamatsu University School of Medicine

发明人： Naohiro Kanayama ,  Kazuo Umemura ,  Takayuki Iwaki ,  Tetsumei Urano ,  Kotomi Ikuma

IPC分类号： G01N33/543

CPC分类号： G01N33/54306 ,  A61K38/57 ,  C07K14/8132 ,  G01N33/689 ,  G01N2333/8132 ,  G01N2800/368

摘要： The present invention relates to a method for diagnosing the degree of risk for preterm delivery or miscarriage, comprising measuring plasminogen activator inhibitor activity or level in plasma. Specifically, the present invention relates to: a method for diagnosing the degree of risk for preterm delivery or miscarriage, wherein when the plasminogen activator inhibitor activity or level is lower than those of normal pregnant woman, the degree of risk for preterm delivery or miscarriage is determined to be high; a kit for the diagnosis of the degree of risk for preterm delivery or miscarriage; and a pharmaceutical composition for the prevention of preterm delivery or miscarriage, comprising plasminogen activator inhibitor-1.

摘要翻译： 本发明涉及一种用于诊断早产或流产风险程度的方法，包括测量血浆中的纤溶酶原激活物抑制剂活性或水平。 具体而言，本发明涉及诊断早产或流产风险程度的方法，其中当纤溶酶原激活物抑制剂活性或水平低于正常孕妇时，早产或流产的风险程度为 确定高; 用于诊断早产或流产风险程度的试剂盒; 以及用于预防早产或流产的药物组合物，其包含纤溶酶原激活物抑制剂-1。

公开(公告)号：US20130267022A1

公开(公告)日：2013-10-10

申请号：US13769144

申请日：2013-02-15

申请人： Intrexon Corporation

发明人： Thomas D. Reed ,  Richard E. Peterson ,  Charles E. Reed ,  Joan Mazzarelli Sopczynski ,  Bethany L. Merenick ,  Jonathan Carson ,  Catherine L. Bair ,  Elena Tasheva

IPC分类号： C07K14/00

CPC分类号： C07K14/001 ,  C07K14/75 ,  C07K14/78 ,  C07K14/8132 ,  C12N9/2451 ,  C12N9/6459 ,  C12N9/6462 ,  C12Y302/01099 ,  C12Y304/21069 ,  C12Y304/21073

摘要： The invention relates to mammalian PAI-I ligands and modulators. In particular, the invention relates to polypeptides, polypeptide compositions and polynucleotides that encode polypeptides that are ligands and/or modulators of PAI-I. The invention also relates to polyligands that are homopolyligands or heteropolyligands that modulate PAI-I activity. The invention also relates to ligands and polyligands localized to a region of a cell. The invention also relates to localization tethers and promoter sequences that can be used to provide spatial control of the PAI-I ligands and polyligands. The invention also relates to inducible gene switches that can be used to provide temporal control of the PAI-I ligands and polyligands. The invention also relates to methods of treating or preventing atherosclerosis. The invention also relates to methods of treating or preventing fibrosis.

摘要翻译： 本发明涉及哺乳动物PAI-1配体和调节剂。 具体地，本发明涉及编码作为PAI-1的配体和/或调节剂的多肽的多肽，多肽组合物和多核苷酸。 本发明还涉及作为调节PAI-1活性的均聚配体或杂多糖的聚合配体。 本发明还涉及位于细胞区域的配体和聚合配体。 本发明还涉及可用于提供PAI-1配体和聚合配体的空间控制的定位系链和启动子序列。 本发明还涉及可用于提供PAI-1配体和聚合配体的时间控制的可诱导基因开关。 本发明还涉及治疗或预防动脉粥样硬化的方法。 本发明还涉及治疗或预防纤维化的方法。

公开(公告)号：US20100221254A1

公开(公告)日：2010-09-02

申请号：US12652998

申请日：2010-01-06

申请人： Linda Fredriksson ,  Hong Li ,  Christina Fieber ,  Xuri Li ,  Ulf Eriksson

发明人： Linda Fredriksson ,  Hong Li ,  Christina Fieber ,  Xuri Li ,  Ulf Eriksson

IPC分类号： A61K39/395 ,  C07K16/00 ,  A61P35/00 ,  A61P9/10

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K14/49 ,  C07K14/8132 ,  C07K16/40 ,  C12N9/6459 ,  C12N9/99 ,  C12Y304/21069

摘要： Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.

摘要翻译： 抑制血管发生的方法包括施用组织纤溶酶原激活剂（tPA）抑制剂和适用于包含tPA抑制剂的方法的药物组合物。 还提供了用于刺激血管生成的方法，其包括向有需要的患者施用tPA，以及包含用于刺激方法的有效量的tPA的药物组合物。 本发明公开了tPA是特异性PDGF-C活化蛋白酶，PDGF-CC中的CUB结构域与蛋白酶直接相互作用，是有效的蛋白水解所必需的，而释放的CUB结构域是tPA抑制剂。 优选地，本发明的方法和组合物用于同时刺激或同时抑制溶栓和血管发生。

公开(公告)号：US07662794B2

公开(公告)日：2010-02-16

申请号：US10512496

申请日：2003-04-23

申请人： Silviu Itescu

发明人： Silviu Itescu

IPC分类号： C07H21/04 ,  A01N43/04 ,  A61K31/70

CPC分类号： C12N15/113 ,  A61K38/00 ,  C07K14/8132 ,  C12N15/1137 ,  C12N2310/12 ,  C12N2310/315

摘要： The present invention provides DNAzymes and ribozymes that specifically cleave PAI-1-encoding mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of PAI-1-encoding mRNA. The invention also provides various methods of inhibiting the expression of PAI-1, and methods of treating diseases by such. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes, antisense oligonucleotides, or other inhibitors of PAI-1 expression as active ingredients.

摘要翻译： 本发明提供了特异性切割编码PAI-1的mRNA的DNA酶和核酶。 本发明还提供了特异性抑制编码PAI-1的mRNA翻译的反义寡核苷酸。 本发明还提供了抑制PAI-1表达的各种方法，以及通过其治疗疾病的方法。 最后，本发明提供含有本发明的酶，酶，反义寡核苷酸或PAI-1表达的其它抑制剂作为活性成分的药物组合物。

公开(公告)号：US07264953B2

公开(公告)日：2007-09-04

申请号：US10197258

申请日：2002-07-18

申请人： Daniel A. Lawrence ,  Natalia Gorlatova ,  David L. Crandall

发明人： Daniel A. Lawrence ,  Natalia Gorlatova ,  David L. Crandall

IPC分类号： C12N9/99

CPC分类号： C07K14/8121 ,  C07K14/81 ,  C07K14/8132 ,  C07K16/38 ,  C12Q1/37 ,  G01N2333/81 ,  G01N2500/04

摘要： A library of mutants of metastable proteins, such as proteinase inhibitors, can be screened for the specific loss of a wild-type capability to bind an antibody, yielding valuable drug-design information which otherwise is unavailable. By this approach, for example, a mutant proteinase inhibitor can be obtained that has the amino acid sequence of a wild-type protein, or an active fragment thereof, save for the presence of one or more mutations in at least one epitope, thereby altering interaction of the mutant with an anti-proteinase inhibitor antibody.

摘要翻译： 可以筛选亚稳态蛋白质突变体的文库，例如蛋白酶抑制剂，以便特异性丧失结合抗体的野生型能力，产生否则不可用的有价值的药物设计信息。 通过这种方法，例如，可以获得具有野生型蛋白质的氨基酸序列或其活性片段的突变蛋白酶抑制剂，除了在至少一个表位中存在一个或多个突变，从而改变 突变体与抗蛋白酶抑制剂抗体的相互作用。

公开(公告)号：US20060104978A1

公开(公告)日：2006-05-18

申请号：US10971705

申请日：2004-10-25

申请人： Linda Fredriksson ,  Hong Li ,  Christina Fieber ,  Xuri Li

发明人： Linda Fredriksson ,  Hong Li ,  Christina Fieber ,  Xuri Li

IPC分类号： A61K39/395

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K14/49 ,  C07K14/8132 ,  C07K16/40 ,  C12N9/6459 ,  C12N9/99 ,  C12Y304/21069

摘要： Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.

公开(公告)号：US20060045878A1

公开(公告)日：2006-03-02

申请号：US11048774

申请日：2005-02-03

申请人： Jian Ni ,  Reiner Gentz ,  Steven Ruben ,  Y. Shi

发明人： Jian Ni ,  Reiner Gentz ,  Steven Ruben ,  Y. Shi

IPC分类号： C07H21/04 ,  A61K39/395 ,  C07K16/44 ,  C12N5/06

CPC分类号： C07K14/81 ,  A61K38/00 ,  A61K48/00 ,  C07K14/8132 ,  C07K2319/00 ,  Y02A50/463

摘要： The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.

摘要翻译： 本发明涉及纤溶酶原激活物抑制剂蛋白家族的新成员。 特别地，提供编码胰腺衍生的纤溶酶原激活物抑制蛋白的分离的核酸分子。 还提供了胰腺来源的纤溶酶原激活物抑制剂多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于治疗生理和病理疾病状况的方法以及用于检测病理学疾病的诊断方法。

公开(公告)号：US20050148527A1

公开(公告)日：2005-07-07

申请号：US10512496

申请日：2003-04-23

申请人： Silviu Itescu

发明人： Silviu Itescu

IPC分类号： C12N15/09 ,  A61K31/122 ,  A61K31/37 ,  A61K31/616 ,  A61K31/7088 ,  A61K31/727 ,  A61K38/00 ,  A61K38/22 ,  A61K38/46 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/02 ,  A61P9/10 ,  A61P11/00 ,  A61P13/12 ,  A61P17/00 ,  A61P27/02 ,  A61P29/00 ,  C07H21/02 ,  C07K14/81 ,  C12N20060101 ,  C12N15/113 ,  C12Q1/68

CPC分类号： C12N15/113 ,  A61K38/00 ,  C07K14/8132 ,  C12N15/1137 ,  C12N2310/12 ,  C12N2310/315

摘要： The present invention provides DNAzymes and ribozymes that specifically cleave PAI-1-encoding mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of PAI-1-encoding mRNA. The invention also provides various methods of inhibiting the expression of PAI-1, and methods of treating diseases by such. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes, antisense oligonucleotides, or other inhibitors of PAI-1 expression as active ingredients.

摘要翻译： 本发明提供了特异性切割编码PAI-1的mRNA的DNA酶和核酶。 本发明还提供了特异性抑制编码PAI-1的mRNA翻译的反义寡核苷酸。 本发明还提供了抑制PAI-1表达的各种方法，以及通过其治疗疾病的方法。 最后，本发明提供含有本发明的酶，酶，反义寡核苷酸或PAI-1表达的其它抑制剂作为活性成分的药物组合物。